Please note: Authors from the Paul-Ehrlich-Institut are highlighted in bold. For online abstracts or full text publications, please follow the links.
Fiedler SA, Henseler O, Hoffelner M, Doll M, Hutschenreuter G, Hoch J, Weinauer F, Humpe A, Funk MB, Hilger A (2023): Monitoring Blood Supply in Germany: A Regulatory Perspective.
Transfus Med Hemother 50: 129-134.
Text
Samukange WT, Kafere C, Heinrich K, Sabblah GT, Siame MM, Chirinda L, Reinhardt J, Hilger A (2023): Strengthening Blood Regulatory Systems to tackle Africa’s unmet needs for blood and blood products.
Transfus Med Hemother 50: 123-128.
Text
Keipert C, Drechsel-Bäuerle U, Oberle D, Müller-Olling M, Hilger A (2021): Epidemiological Challenges in Rare Bleeding Disorders: FVIII Inhibitor Incidence in Haemophilia A Patients - A Known Issue of Unknown Origin.
Int J Environ Res Public Health 18: 225.
Online-Abstract
Konkle BA, Recht M, Hilger A, Marks P (2021): The critical need for postmarketing surveillance in gene therapy for haemophilia.
Haemophilia 27: 126-131.
Text
Müller-Olling M, Vahlensieck U, Hilger A (2021): Heterogeneity in COVID-19 Convalescent Plasma Clinical Trials.
Clin Pharmacol Ther 111: 995-1000.
Text
Duda H, Hesse J, Haschberger B, Hilger A, Keipert C (2020): The German Hemophilia Registry: Growing with Its Tasks.
J Clin Med 9: E3408.
Online-Abstract
Fiedler SA, Boller K, Junker AC, Kamp C, Hilger A, Schwarz W, Seitz R, Salge-Bartels U (2020): Evaluation of the in vitro function of platelet concentrates from pooled buffy coats or apheresis.
Transfus Med Hemother 47: 314-324.
Text
Keipert C, Müller-Olling M, Gauly F, Arras-Reiter C, Hilger A (2020): Annual Bleeding Rates: Pitfalls of Clinical Trial Outcomes in Hemophilia Patients.
Clin Transl Sci 13: 1127-1136.
Text
Ovanesov MV, Williams SC, Nübling CM, Dodt J, Hilger A, Maryuningsih Y, Gray E (2020): Summary of the WHO hearing on the development of product-specific reference materials for coagulation factor VIII and factor IX products.
Biologicals 67: 88-93.
Online-Abstract
Peyvandi F, Berger K, Seitz R, Hilger A, Hecquet ML, Wierer M, Buchheit KH, O'Mahony B, Bok A, Makris M, Mansmann U, Schramm W, Mannucci PM (2020): Kreuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies.
Haemotologica 105: 2038-2043.
Text
Pierce GF, Coffin D, Members of the WFH Gene Therapy Round Table Program Committee and Orgazining Committee, Lillicrap D, Ozelo M, Pasi J, Rotellini D, Marquez S, Sannié T, Srivastava A, den Berg M, Weill A, Almeida A, Baumann A, Brooker M, Durante L, Naccache M, Robinson F, Bagley L, Chapin J, Diop S, El Ekiaby M, Flume M, George L, Grehan J, Hawe M, High K, Hilger A, Jonsson B, Kim J, Kimmelman J, Kobelt G, Lee M, Lillicrap D, Linares A, Lozier J, Mahlangu J, Makris M, Marten K, Mathew P, Noone D, O'Hara J, Ozelo M, Ohmori T, Page D, Pasi J, Perry J, Pierce G, Hernandez P, Ragni M, Rakha M, Rayner B, Reiss U, Rollmann D, Rotellini D, Ruff P, Ruiz S, Marquez S, Sannié T, Sathyanarayanan R, Skinner M, Srivastava A, Tortella B, Tuddenham E, Valentino L, den Berg M, Vandendriessche T, Weill A, Yang R, Zelenkofske S (2019): The 1st WFH Gene Therapy Round Table: Understanding the landscape and challenges of gene therapy for haemophilia around the world.
Haemophilia 25: 189-194.
Text
Keipert C, Jonker CJ, van den Berg HM, Hilger A (2018): Clinical trials and registries in haemophilia: Opponents or collaborators? Comparison of PUP data derived from different data sources.
Haemophilia 24: 420-428.
Online-Abstract
Giangrande PL, Peyvandi F, O'Mahony B, Behr-Gross ME, Hilger A, Schramm W, Mannucci PM (2017): Kreuth IV: European consensus proposals for treatment of haemophilia with coagulation factor concentrates.
Haemophilia 23: 370-375.
Online-Abstract
Lacroix-Desmazes S, Scott DW, Goudemand J, Van Den Berg M, Makris M, Van Velzen AS, Santagostino E, Lillicrap D, Rosendaal FR, Hilger A, Sauna ZE, Oldenburg J, Mantovani L, Mancuso ME, Kessler C, Hay CR, Knoebl P, Di Minno G, Hoots K, Bok A, Brooker M, Buoso E, Mannucci PM, Peyvandi F (2017): Summary report of the First International Conference on inhibitors in haemophilia A.
Blood Transfus 15: 568-576.
Online-Abstract
Keipert C, Hilger A (2016): Response to Italian registries on bleeding disorders.
Clin Pharmacol Ther 99: 273.
Keipert C, van den Berg HM, Keller-Stanislawski B, Hilger A (2016): Haemophilia registries to complement clinical trial data: a pious hope or an urgent necessity? Reflections on a possible way forward.
Haemophilia 22: 647-650.
Online-Abstract
Berger K, Schopohl D, Hilger A, Behr Gross ME, Giangrande P, Peyvandi F, Seitz R, Schramm W (2015): Research in haemophilia B - approaching the request for high evidence levels in a rare disease.
Haemophilia 21: 4-20.
Online-Abstract
Keipert C, Hesse J, Haschberger B, Heiden M, Seitz R, van den Berg HM, Hilger A (2015): The growing number of hemophilia registries: Quantity versus quality.
Clin Pharmacol Ther 97: 492-501.
Online-Abstract
Vahlensieck U, Poley-Ochmann S, Hilger A, Heiden M, Seitz R (2015): Genehmigungsverfahren für Gewebezubereitungen und Blutstammzellzubereitungen zur hämatopoetischen Rekonstitution : Dokumentation klinischer und nicht klinischer Daten mittels eines Zentralgutachtens.
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 58: 1247-1253.
Online-Abstract
Giangrande P, Seitz R, Behr-Gross ME, Berger K, Hilger A, Klein H, Schramm W, Mannucci PM (2014): Kreuth III: European consensus proposals for treatment of haemophilia with coagulation factor concentrates.
Haemophilia 20: 322-325.
Online-Abstract
Hilger A, Arras-Reiter C, Keller-Stanislawski B, Ljungberg B, Male C, Mentzer D, Seitz R, Silvester G: Comment on: Mannucci, P. M. Evolution of the European guidelines for the clinical development of factor VIII products.
Haemophilia 19: 349-350.
Seitz R, Hilger A, Heiden M (2012): Bone Marrow, Peripheral Blood, or Umbilical Cord Blood: Does the Source of Allogeneic Hematopoietic Progenitor Cells Matter?.
J Blood Disord Transfus S1: 007.
Fulltext
Hilger A, Kerr J (2009): EU regulatory perspective on rare diseases: Focus on plasma protein related disorders.
Pharmaceuticals Policy and Law 11: 387-395.
Neugebauer B, Drai C, Haase M, Hilger A, Keller-Stanislawski B, Laitinen-Parkkonen P, Mentzer D, Rasmussen C, Ratignier C, Seitz R (2008): Factor VIII products and inhibitor development: concepts for revision of European regulatory guidelines.
Haemophilia 14: 142-144.
Online-Abstract
Hilger A, Heiden M, Seitz R (1999): "Künstliches Blut": Entwicklung von Blutersatzstoffen auf Hämoglobinbasis: Hintergrund, Strategien und offene Fragen.
Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 42: 113-117.
Online-Abstract
Text
